This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Komazin, G.
Right arrow Articles by Drach, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komazin, G.
Right arrow Articles by Drach, J. C.

 Previous Article  |  Next Article 

Journal of Virology, November 2003, p. 11499-11506, Vol. 77, No. 21
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.21.11499-11506.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Resistance of Human Cytomegalovirus to the Benzimidazole L-Ribonucleoside Maribavir Maps to UL27

Gloria Komazin,1,2 Roger G. Ptak,1,{dagger} Brian T. Emmer,1 Leroy B. Townsend,2 and John C. Drach1,2*

Department of Biologic and Materials Sciences, School of Dentistry,1 Interdepartmental Graduate Program in Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 481092

Received 5 March 2003/ Accepted 5 August 2003

1-(ß-D-Ribofuranosyl)-2,5,6-trichlorobenzimidazole (TCRB) and its 2-bromo analog, BDCRB, are potent and selective inhibitors of human cytomegalovirus (HCMV) DNA processing and packaging. Since they are readily metabolized in vivo, analogs were synthesized to improve biostability. One of these, 1-(ß-L-ribofuranosyl)-2-isopropylamino-5,6-dichlorobenzimidazole (1263W94; maribavir), inhibits viral DNA synthesis and nuclear egress. Resistance to maribavir was mapped to UL97, and this viral kinase was shown to be a direct target of maribavir. In the present study, an HCMV strain resistant to TCRB and BDCRB was passaged in increasing concentrations of maribavir, and resistant virus was isolated. This strain (G2) grew at the same rate as the wild-type virus and was resistant to both BDCRB and maribavir. Resistance to BDCRB was expected, because the parent strain from which G2 was isolated was resistant due to known mutations in UL56 and UL89. However, no mutations were found in UL97 or other relevant open reading frames that could explain resistance to maribavir. Because sequencing of selected HCMV genes did not identify the resistance mutation, a cosmid library was made from G2, and a series of recombinant G2 wild-type viruses were constructed. Testing the recombinants for sensitivity to maribavir narrowed the locus of resistance to genes UL26 to UL32. Sequencing identified a single coding mutation in ORF UL27 (Leu335Pro) as the one responsible for resistance to maribavir. These results establish that UL27 is either directly or indirectly involved in the mechanism of action of maribavir. They also suggest that UL27 could play a role in HCMV DNA synthesis or egress of HCMV particles from the nucleus.

* Corresponding author. Mailing address: School of Dentistry, 1011 N. University Ave., University of Michigan, Ann Arbor, MI 48109-1078. Phone: (734) 763-5579. Fax: (734) 764-4497. E-mail: jcdrach{at}umich.edu.

{dagger} Present address: Southern Research Institute, Frederick, MD 21701.

Journal of Virology, November 2003, p. 11499-11506, Vol. 77, No. 21
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.21.11499-11506.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chou, S. (2009). Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir. Antimicrob. Agents Chemother. 53: 81-85 [Abstract] [Full Text]  
  • Chou, S., Marousek, G. I. (2008). Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant. J. Virol. 82: 246-253 [Abstract] [Full Text]  
  • Hwang, J.-S., Kregler, O., Schilf, R., Bannert, N., Drach, J. C., Townsend, L. B., Bogner, E. (2007). Identification of Acetylated, Tetrahalogenated Benzimidazole D-Ribonucleosides with Enhanced Activity against Human Cytomegalovirus. J. Virol. 81: 11604-11611 [Abstract] [Full Text]  
  • Prichard, M. N., Britt, W. J., Daily, S. L., Hartline, C. B., Kern, E. R. (2005). Human Cytomegalovirus UL97 Kinase Is Required for the Normal Intranuclear Distribution of pp65 and Virion Morphogenesis. J. Virol. 79: 15494-15502 [Abstract] [Full Text]  
  • Gershburg, E., Pagano, J. S. (2005). Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother 56: 277-281 [Abstract] [Full Text]  
  • Gilbert, C., Boivin, G. (2005). Human Cytomegalovirus Resistance to Antiviral Drugs. Antimicrob. Agents Chemother. 49: 873-883 [Full Text]  
  • Herget, T., Freitag, M., Morbitzer, M., Kupfer, R., Stamminger, T., Marschall, M. (2004). Novel Chemical Class of pUL97 Protein Kinase-Specific Inhibitors with Strong Anticytomegaloviral Activity. Antimicrob. Agents Chemother. 48: 4154-4162 [Abstract] [Full Text]  
  • Evers, D. L., Komazin, G., Ptak, R. G., Shin, D., Emmer, B. T., Townsend, L. B., Drach, J. C. (2004). Inhibition of Human Cytomegalovirus Replication by Benzimidazole Nucleosides Involves Three Distinct Mechanisms. Antimicrob. Agents Chemother. 48: 3918-3927 [Abstract] [Full Text]  
  • Chou, S., Marousek, G. I., Senters, A. E., Davis, M. G., Biron, K. K. (2004). Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir. J. Virol. 78: 7124-7130 [Abstract] [Full Text]  
  • Kern, E. R., Hartline, C. B., Rybak, R. J., Drach, J. C., Townsend, L. B., Biron, K. K., Bidanset, D. J. (2004). Activities of Benzimidazole D- and L-Ribonucleosides in Animal Models of Cytomegalovirus Infections. Antimicrob. Agents Chemother. 48: 1749-1755 [Abstract] [Full Text]  
  • Gershburg, E., Hong, K., Pagano, J. S. (2004). Effects of Maribavir and Selected Indolocarbazoles on Epstein-Barr Virus Protein Kinase BGLF4 and on Viral Lytic Replication. Antimicrob. Agents Chemother. 48: 1900-1903 [Abstract] [Full Text]  
  • Komazin, G., Townsend, L. B., Drach, J. C. (2004). Role of a Mutation in Human Cytomegalovirus Gene UL104 in Resistance to Benzimidazole Ribonucleosides. J. Virol. 78: 710-715 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»